| abstract |
THEY REFER TO ANTIBACTERIALS OF FORMULA (I), WHERE: "A" IS OXYGEN OR SULFUR; "D" IS HYDROGEN, ALKYL OR C1-C9 ALKYLENE (OPTIONALLY SUBSTITUTED FOR CYAN OR HYDROXYL), - (CO) a-NR2R3, - (CT) d-NR10R11, - (CO) e-NR12-CO-NR13R14 or - CO-R20, AMONG OTHERS, WHERE: "T" IS OXYGEN OR SULFUR; a, d Y e ARE 0 or 1; R2, R3, R10, R11, R12, R13 AND R14 ARE H or C1-C5 ALKYL, AMONG OTHERS; R20 IS ARYL C6-C10 OPTIONALLY REPLACED BY HALOGEN; "E" AND "L" PREFERABLY ARE HYDROGEN; R1 IS AZIDO, HYDROXYL, -OR21, -O-SO2R22 or -NR23R24, WHERE: R21 IS C1-C6 ACIL or A PROTECTIVE GROUP OH; R22 IS C1-C5-ALKYL, PHENYL or TOLYL; R23 AND R24 ARE HYDROGEN, ALCOXI C1-C6 or -CT`-R25, AMONG OTHERS, WHERE: T 'IS LIKE "T"; R25 IS C3-C6 CYCLLOALKYL, C1-C6 ALKYL, C1-C5 THIOALKYL or C1-C5 ACIL, AMONG OTHERS. IT ALSO REFERS TO THE INTERMEDIATE COMPOUNDS OF FORMULA (VII), TO THE N-1-OXIDES OF COMPOUND (VII) AND TO THE COMPOUND OF FORMULA (IV). FURTHER REFERS TO THE PREPARATION PROCEDURES OF THE FORMULA (I) COMPOUNDS, WHICH INCLUDES: a) TRANSFORMING THE N-1-OXIDES OF THE FORMULA (VII) COMPOUND BY REACTION WITH Ac2O or p-TsCl / CO3K2 IN INERT SOLVENTS, or b) TRANSFORM (IV) THROUGH REACTION WITH ALKYL-LITHIUM IN ETHERS AND R-GLYCIDYL BUTYRATE, AND OTHER PROCESSES TO OBTAIN THE SUBSTITUTES IN R1 |